Business Development (11)

Challenge A private investment firm was seeking an independent reality-check on a potential investment in a pharmaceutical company that had recently in-licensed a generic therapeutic asset. The firm...

Challenge A small molecule pharmaceutical incubator is using a novel and proprietary drug discovery and translational platform to develop first-in-class, small molecule therapeutics for the treatment...

Alacrita provides both in- and out-licensing support to a number of pharmaceutical and biotech organizations and companies. Below you'll find a series of case studies related to this service.

Challenge Alacrita’s pharma consultants were engaged to conduct a due diligence and valuation of a Phase II dermatology asset.

Challenge A well-capitalized cancer immunotherapy company, operating in a highly competitive field, needed to benchmark its financial status and staff numbers against its peers to help gauge its...

Challenge A start-up company was planning to license an immunomodulatory product from a European pharmaceutical company. The therapy had been unsuccessfully tried in allergic disorders, but the...

Challenge A private biotech company was preparing for an IPO. The company was developing a first-in-class small molecule inhibitor with the potential to treat a range of tumor types. The company was...

Challenge A biotech company engaged in licensing discussions with a number of major pharma companies needed help with risk adjusted NPV (rNPV) valuations for each program.

Challenge A licensor of a marketed oncology drug needed support with monetizing its royalty stream. Alacrita was engaged to develop an independent market-based valuation of the product.

Challenge A drug discovery company was in discussions with a big pharma about collaborating on a number of strategies that would deliver at least one quality clinical candidate. The pharma company...

Challenge A virtual life science company had raised money from angel investors and anticipated a clinical development strategy for their product targeting two major cancer indications. The client...

Challenge A company developing a novel wound care product was embarking on a significant clinical trial program. It was planning an investor exit in the next 24 months and therefore wanted to connect...